Condensed Consolidated Statements Of Operations (USD $)	3 Months Ended		9 Months Ended
	Mar. 31, 2012	Mar. 31, 2011	Mar. 31, 2012	Mar. 31, 2011
Net revenues:
Product revenue	$ 6,065,931	$ 6,399,159	$ 18,365,885	$ 19,075,536
Other revenue	0	0	0	6,933
Revenues, net	6,065,931	6,399,159	18,365,885	19,082,469
Costs and expenses:
Cost of goods sold	3,593,302	4,068,483	11,446,127	12,335,468
Marketing, general and administrative	2,621,482	2,715,690	7,669,231	8,157,077
Research and development	413,874	395,656	1,116,414	1,198,273
Goodwill impairment	0	905,810	0	905,810
Total costs and expenses	6,628,658	8,085,639	20,231,772	22,596,628
Loss from operations	(562,727)	(1,686,480)	(1,865,887)	(3,514,159)
Other (expense) and income:
Equity in Ocular Telehealth Management, LLC	(532)	(37,600)	612	(71,745)
Loss on disposal of assets	0	0	(86,885)	0
Interest income	17	83	119	194
Interest expense	(76,544)	(84,186)	(247,094)	(244,064)
Total other (expense) income	(77,059)	(121,703)	(333,248)	(315,615)
Loss from continuing operations before taxes	(639,786)	(1,808,183)	(2,199,135)	(3,829,774)
Provision for income taxes	0	0	0	0
Net loss from continuing operations	(639,786)	(1,808,183)	(2,199,135)	(3,829,774)
Net income (loss) from discontinued operations	0	(113,302)	(2,765,300)	210,525
Net loss	$ (639,786)	$ (1,921,485)	$ (4,964,435)	$ (3,619,249)
Net income (loss) per share
Continuing operations	$ (0.09)	$ (0.24)	$ (0.29)	$ (0.51)
Discontinued operations	$ 0.00	$ (0.02)	$ (0.37)	$ 0.03
Net income (loss)	$ (0.09)	$ (0.26)	$ (0.66)	$ (0.48)
Net loss per share Diluted:
Continuing operations	$ (0.09)	$ (0.24)	$ (0.29)	$ (0.51)
Discontinued operations	$ 0.00	$ (0.02)	$ (0.37)	$ 0.03
Net income (loss)	$ (0.09)	$ (0.26)	$ (0.66)	$ (0.48)
Weighted average shares - basic	7,526,430	7,526,430	7,526,430	7,526,430
Weighted average shares - diluted	7,526,430	7,526,430	7,526,430	7,526,430